ConductScience.org, home

Paper12790806

Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.

Starkey KJ and 5 others. J Mol Endocrinol, 2003. Cited by 69 papers, by iCite.

Cite this record

ConductScience Library. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. Papers, record 12790806. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12790806

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.
PubMed
Journal
J Mol Endocrinol
PubMed
Year
2003
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
69
iCite
Relative citation ratio, by iCite
1.66
iCite
Revised in PubMed
2019-10-25
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Starkey KJK J
2Janezic AA
3Jones GG
4Jordan NN
5Baker GG
6Ludgate MM

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adipose TissueMajor topic
Graves DiseaseMajor topic
Receptors, ThyrotropinMajor topic
Animals
Base Sequence
DNA Primers
Humans
Mice
Mice, Inbred BALB C

Source PubMed

Download CSV of topics

Cited by42

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.

PMIDTitleJournalYearIn PapersSource
41837138Maraviroc attenuates orbital remodeling, inflammation, and lipid dysregulation in a murine model of thyroid eye disease associated with Graves' disease.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/41837138PubMed
41728592The therapeutic revolution in thyroid eye disease: from orbital radiotherapy to teprotumumab and AI.Front Med (Lausanne)2026https://conductscience.org/library/papers/41728592PubMed
40605078Thyroid hormone signaling in ocular development and diseases.Biol Res2025https://conductscience.org/library/papers/40605078PubMed
38273183Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.Pharmacol Rep2024https://conductscience.org/library/papers/38273183PubMed
37870639TSH receptor autoantibody levels post-total thyroidectomy in Graves' ophthalmopathy: a meta-analysis.Langenbecks Arch Surg2023https://conductscience.org/library/papers/37870639PubMed
37435490Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37435490PubMed
37080243Thyrotropin Receptor Autoantibody Assessment in Thyroid Eye Disease: Does the Assay Type Matter?Korean J Ophthalmol2023https://conductscience.org/library/papers/37080243PubMed
35903283The Mysterious Universe of the TSH Receptor.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/35903283PubMed
35566351Different Effects of Cigarette Smoke, Heated Tobacco Product and E-Cigarette Vapour on Orbital Fibroblasts in Graves' Orbitopathy; a Study by Real Time Cell Electronic Sensing.Molecules2022https://conductscience.org/library/papers/35566351PubMed
34899596Orbital Signaling in Graves' Orbitopathy.Front Endocrinol (Lausanne)2021https://conductscience.org/library/papers/34899596PubMed
34889904Expression of Endogenous Putative TSH Binding Protein in Orbit.Curr Issues Mol Biol2021https://conductscience.org/library/papers/34889904PubMed
31889140New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.Nat Rev Endocrinol2020https://conductscience.org/library/papers/31889140PubMed
31844169Fibrosis in dysthyroid eye disease.Eye (Lond)2020https://conductscience.org/library/papers/31844169PubMed
31781640Immunological Aspects of Graves' Ophthalmopathy.Biomed Res Int2019https://conductscience.org/library/papers/31781640PubMed
30414981Molecular biomarkers of Graves' ophthalmopathy.Exp Mol Pathol2019https://conductscience.org/library/papers/30414981PubMed
29320711Anatomical, Physiological, and Functional Diversity of Adipose Tissue.Cell Metab2018https://conductscience.org/library/papers/29320711PubMed
28539287[Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].Nan Fang Yi Ke Da Xue Xue Bao2017https://conductscience.org/library/papers/28539287PubMed
28469599The Role of Thyrotropin Receptor Activation in Adipogenesis and Modulation of Fat Phenotype.Front Endocrinol (Lausanne)2017https://conductscience.org/library/papers/28469599PubMed
24302624A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells.Endocrinology2014https://conductscience.org/library/papers/24302624PubMed
24286160Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis.Arthritis Res Ther2013https://conductscience.org/library/papers/24286160PubMed

See all 42 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TSHR7253PubTator's text mininghttps://conductscience.org/library/genes/7253

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12790806

GET https://conductscience.org/api/papers/v1/12790806/cited_by?page=2